Advanced Biomed (NASDAQ:ADVB – Get Free Report) issued its earnings results on Friday. The company reported $0.32 earnings per share (EPS) for the quarter, Zacks reports.
Advanced Biomed Stock Up 1.1%
NASDAQ ADVB opened at $0.24 on Friday. The company has a market cap of $5.19 million and a P/E ratio of 1.26. Advanced Biomed has a one year low of $0.21 and a one year high of $4.10.
Wall Street Analyst Weigh In
Separately, Weiss Ratings started coverage on shares of Advanced Biomed in a research note on Monday, January 26th. They set a “sell (e+)” rating on the stock. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Advanced Biomed presently has an average rating of “Sell”.
Advanced Biomed Company Profile
Our Mission We are committed to the application research of integrating semiconductor technology and biotechnology. Through the enrichment, capture, and identification of circulating tumor cells and related tumor marker cells in the field of liquid biopsy, we aim to provide cancer patients with rapid and affordable assay products and services. These services include early screening and detection, diagnosis and staging, treatment selection, and patient outcome interventions for cancer. We are a holding company incorporated in the State of Nevada.
Read More
- Five stocks we like better than Advanced Biomed
- Your Bank Account Is No Longer Safe
- Nvidia CEO Issues Bold Tesla Call
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
- The day the gold market broke
Receive News & Ratings for Advanced Biomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advanced Biomed and related companies with MarketBeat.com's FREE daily email newsletter.
